Patient perspectives on fluticasone–vilanterol versus other corticosteroid combination products for the treatment of asthma
Conclusion: Individuals may have drug- and device-specific preferences that should be incorporated into therapeutic decision making. Limited data indicate that clinical and patient-oriented efficacy/safety outcomes of FF–VI are likely comparable to other available combinations for adults with asthma. Patient-friendly features include once-daily dosing, flexibility of dose timing, and design/ease of the use of the device. Additional larger and long-term comparative studies are needed to determine whether these features translate into greater efficacy, safety, patient preference, or adherence versus other ICS–LAB...
Source: Patient Preference and Adherence - May 12, 2016 Category: Global & Universal Tags: Patient Preference and Adherence Source Type: research
Umeclidinium/vilanterol dry-powder inhaler in chronic obstructive pulmonary disease: a guide to its use in the EU
Abstract
Umeclidinium/vilanterol (Anoro®; Laventair™) delivered via a dry-powder inhaler (Ellipta™) is a fixed-dose combination of a long-acting muscarinic receptor antagonist (umeclidinium) and a long-acting β2-adrenoceptor agonist (vilanterol). Once-daily umeclidinium/vilanterol 55/22 µg (delivered dose) is an effective and well tolerated maintenance bronchodilator treatment option for relieving the symptoms of chronic obstructive pulmonary disease (COPD). In clinical trials, umeclidinium/vilanterol improved pulmonary function to a significantly greater extent than placebo or its individual comp...
Source: Drugs and Therapy Perspectives - May 11, 2016 Category: Drugs & Pharmacology Source Type: research
Chinese Herbal Medicine and Salmeterol and Fluticasone Propionate for Chronic Obstructive Pulmonary Disease: Systematic Review and Network Meta-Analysis
This study is a systematic review of randomized controlled trials (RCTs) with network meta-analyses (NMAs).
Eight electronic databases were searched. Data from RCTs were extracted for random effect pairwise meta-analyses. Pooled relative risk (RR) with 95% confidence interval (CI) was used to quantify the impact of CHM and SFP on forced expiratory volume in 1 second (FEV1), St George's Respiratory Questionnaire (SGRQ) scoring, and 6-Minute Walk Test (6MWT). NMA was used to explore the most effective CHM when used with SFP.
Eleven RCTs (n = 925) assessing 11 different CHM were included. Result from pairwise meta-ana...
Source: Medicine - May 1, 2016 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research
Corticosteroid modulation of immunoglobulin expression and B-cell function in COPD [Research Communication]
We investigated changes in gene expression that occur in chronic obstructive pulmonary disease (COPD) after corticosteroid treatment and sought to identify the mechanisms that regulate these changes. Biopsy samples were taken from patients with COPD (Global Initiative for Chronic Obstructive Lung Disease stage I to II) before and after treatment with fluticasone propionate (FP)/salmeterol (SM) (50/500, 4 wk). Gene expression was measured by microarray and was confirmed by real-time reverse transcription–quantitative PCR (RT-qPCR). The effect of FP on IgG expression and B-cell proliferation in the presence of oxidativ...
Source: FASEB Journal - April 28, 2016 Category: Biology Authors: Lee, J., Machin, M., Russell, K. E., Pavlidis, S., Zhu, J., Barnes, P. J., Chung, K. F., Adcock, I. M., Durham, A. L. Tags: Research Communication Source Type: research
Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial
Publication date: Available online 7 April 2016 Source:The Lancet Respiratory Medicine Author(s): Henrik Watz, Kay Tetzlaff, Emiel F M Wouters, Anne Kirsten, Helgo Magnussen, Roberto Rodriguez-Roisin, Claus Vogelmeier, Leonardo M Fabbri, Pascal Chanez, Ronald Dahl, Bernd Disse, Helen Finnigan, Peter M A Calverley Background Blood eosinophil counts might predict response to inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD) and a history of exacerbations. We used data from the WISDOM trial to assess whether patients with COPD with higher blood eosinophil...
Source: The Lancet Respiratory Medicine - April 7, 2016 Category: Respiratory Medicine Source Type: research
Batch-To-Batch Pharmacokinetic Variability Confounds Current Bioequivalence Regulations: A Dry Powder Inhaler Randomized Clinical Trial.
This article is protected by copyright. All rights reserved.
PMID: 27037630 [PubMed - as supplied by publisher] (Source: Clinical Pharmacology and Therapeutics)
Source: Clinical Pharmacology and Therapeutics - April 1, 2016 Category: Drugs & Pharmacology Authors: Getz EB, Carroll KJ, Jones B, Benet LZ Tags: Clin Pharmacol Ther Source Type: research
FP/FORM Versus FP/SAL Within Clinical Practice: An Updated Budget Impact Analysis in Asthma
Conclusion
The use of FP/FORM as an alternative to FP/SAL can result in cost savings for the NHS when assessing drug, administration, monitoring and adverse events costs. The inclusion of data released since the launch of FP/FORM within the budget impact analysis demonstrates that the potential cost savings to the NHS that were previously published are being translated to clinical practice.
Funding
Mundipharma, UK. (Source: Advances in Therapy)
Source: Advances in Therapy - March 25, 2016 Category: Drugs & Pharmacology Source Type: research
Step-down therapy in well-controlled asthmatic patients using salmeterol xinafoate/fluticasone propionate combination therapy
Conclusion: This study suggests that a balanced step-down protocol, including both ICS and LABA, is essential in providing long-term stability to patients with mild-to-moderate well-controlled asthma. Keywords: long-term outcome, asthma, fluticasone propionate, salmeterol, step down (Source: Journal of Asthma and Allergy)
Source: Journal of Asthma and Allergy - March 18, 2016 Category: Allergy & Immunology Tags: Journal of Asthma and Allergy Source Type: research
Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies.
Authors: Siler TM, Kerwin E, Singletary K, Brooks J, Church A
Abstract
Combinations of drugs with distinct and complementary mechanisms of action may offer improved efficacy in the treatment of chronic obstructive pulmonary disease (COPD). In two 12-week, double-blind, parallel-group studies, patients with COPD were randomized 1:1:1 to once-daily umeclidinium (UMEC; 62.5 μg and 125 μg)
or placebo (PBO), added to twice-daily fluticasone propionate/salmeterol (FP/SAL; 250/50 μg). In both studies, the primary efficacy measure was trough forced expiratory volume in 1 second (FEV1) at Day 85. Secondary en...
Source: COPD: Journal of Chronic Obstructive Pulmonary Disease - February 18, 2016 Category: Respiratory Medicine Tags: COPD Source Type: research
Early COPD Exacerbation Treatment with Combination of ICS and LABA for Patients Presenting with Mild-to-Moderate Worsening of Dyspnea.
Authors: Bourbeau J, Sedeno MF, Metz K, Li PZ, Pinto L
Abstract
This is a proof of concept study that aims to establish feasibility and safety of a new strategy that includes an action plan for early treatment of acute exacerbations of COPD (AECOPD) with doubling dose of a combination of a long-acting beta2 agonist and an inhaled corticosteroid, and to explore its potential for avoiding the requirement of prednisone and its safety. Thirty-seven COPD outpatients with previous exacerbations were enrolled and followed-up for 12 months. The written action plan included a standing prescription to be used in th...
Source: COPD: Journal of Chronic Obstructive Pulmonary Disease - February 18, 2016 Category: Respiratory Medicine Tags: COPD Source Type: research
Economic evaluations of fluticasone-propionate/salmeterol combination therapy for chronic obstructive pulmonary disease: a review of published studies.
Authors: Roberts MH, Borrego ME, Kharat AA, Marshik PL, Mapel DW
Abstract
This review identifies and evaluates the comprehensive reporting of peer-reviewed economic evaluations of the effectiveness of fluticasone-propionate/salmeterol combination (FSC) therapy for maintenance treatment of chronic obstructive pulmonary disease (COPD). Economic evaluations were included if published in English since 2003. Evaluation categories included in the review were cost-effectiveness, cost-utility, and cost-consequence analyses. FSC is cost-effective in comparison to short-acting bronchodilators (SABDs). Cost and outco...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 13, 2016 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
Systemic Exposures of Fluticasone Propionate and Salmeterol Following Inhalation via Metered Dose Inhaler with the Mini Spacer Compared with the Aerochamber Plus Spacer
Journal of Aerosol Medicine and Pulmonary Drug Delivery , Vol. 0, No. 0. (Source: Journal of Aerosol Medicine and Pulmonary Drug Delivery)
Source: Journal of Aerosol Medicine and Pulmonary Drug Delivery - January 28, 2016 Category: Respiratory Medicine Authors: Rashmi MehtaMickael MontembaultFrancis WarrenAshutosh GuptaNoushin BrealeyAlison Moore Source Type: research
Blood eosinophils and inhaled corticosteroid/long-acting {beta}-2 agonist efficacy in COPD
Discussion
Baseline blood eosinophil levels may represent an informative marker for exacerbation reduction with ICS/LABA in patients with COPD and a history of moderate/severe exacerbations. (Source: Thorax)
Source: Thorax - January 14, 2016 Category: Respiratory Medicine Authors: Pavord, I. D., Lettis, S., Locantore, N., Pascoe, S., Jones, P. W., Wedzicha, J. A., Barnes, N. C. Tags: Open access, Drugs: respiratory system Chronic obstructive pulmonary disease Source Type: research
A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in asthma-COPD overlap syndrome
Conclusions FF/VI, the first once-daily ICS/LABA, can provide substantial improvement in lung functions, indicating that FF/VI should be considered for the regular treatment of ACOS. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - January 12, 2016 Category: Respiratory Medicine Source Type: research
Tiotropium/Olodaterol: A Review in COPD
Abstract
Tiotropium/olodaterol (Stiolto™ Respimat®, Spiolto™ Respimat®) is a fixed-dose combination of the long-acting antimuscarinic agent tiotropium bromide (hereafter referred to as tiotropium) and the long-acting β2-adrenoreceptor agonist olodaterol delivered via the Respimat® Soft Mist™ inhaler. It is indicated for the maintenance treatment of airflow obstruction in adults with COPD. Several randomized, phase III studies of 6–52 weeks’ duration evaluated the efficacy of once-daily tiotropium/olodaterol in patients with GOLD stage 2–3 or 2–4 COPD. Tiotropium/olodaterol maintenance t...
Source: Drugs - December 18, 2015 Category: Drugs & Pharmacology Source Type: research
